scholarly journals Galangin Protects against Symptoms of Dextran Sodium Sulfate-Induced Acute Colitis by Activating Autophagy and Modulating the Gut Microbiota

Nutrients ◽  
2020 ◽  
Vol 12 (2) ◽  
pp. 347 ◽  
Author(s):  
Hongzhuan Xuan ◽  
Aiqun Ou ◽  
Shengyu Hao ◽  
Jiajun Shi ◽  
Xiaolu Jin
Keyword(s):  
Gut Microbiota ◽  
Activity Index ◽  
Disease Activity Index ◽  
Short Chain Fatty Acids ◽  
Control Group ◽  
Necrosis Factor Alpha ◽  
Bowel Diseases ◽  
Pre Treatment ◽  
Related Proteins

Galangin is a natural flavonoid that has been reported to provide substantial health benefits. Nevertheless, little is known about the potential effects of galangin against inflammatory bowel diseases. Here, an in vivo study was performed to investigate the preventive effects of galangin against dextran sulphate sodium (DSS)-induced acute murine colitis, which mimics the symptoms of human ulcerative colitis (UC). Pre-treatment with galangin (15 mg/kg, p.o.) resulted in a significant decreased in the macroscopic signs of DSS-induced colitic symptoms, including a decreased disease activity index, prevention of the colon length shortening, and alleviation of the pathological changes occurring in the colon. Colonic pro-inflammatory mediators, including tumor necrosis factor-alpha, interleukin (IL)-1 beta, and IL-6, as well as myeloperoxidase activities were decreased following galangin pre-treatment when compared with the DSS control group. Moreover, galangin pre-treatment significantly increased the expressions of autophagy-related proteins and promoted the formation of autophagosome in the colon. Galangin pre-treatment increased the diversity of the gut microbiota, and this was accompanied by increased levels of short-chain fatty acids. These observed changes could involve the modulating effects conferred by galangin in relation to some specific bacteria populations, including the recovery of Lactobacillus spp., and increased Butyricimonas spp. Overall, these results support the use of galangin in the prevention of UC.

scholarly journals In Vivo Healthy Benefits of Galacto-Oligosaccharides from Lupinus albus (LA-GOS) in Butyrate Production through Intestinal Microbiota

Biomolecules ◽  
2021 ◽  
Vol 11 (11) ◽  
pp. 1658
Author(s):  
Lucila A. Godínez-Méndez ◽  
Carmen M. Gurrola-Díaz ◽  
José Sergio Zepeda-Nuño ◽  
Natali Vega-Magaña ◽  
Rocio Ivette Lopez-Roa ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Activity Index ◽  
Lupinus Albus ◽  
Disease Activity Index ◽  
Short Chain Fatty Acids ◽  
Treated Group ◽  
Cell Number ◽  
Coa Transferase ◽  
Ph Level

Animal digestive systems host microorganism ecosystems, including integrated bacteria, viruses, fungi, and others, that produce a variety of compounds from different substrates with healthy properties. Among these substrates, α-galacto-oligosaccharides (GOS) are considered prebiotics that promote the grow of gut microbiota with a metabolic output of Short Chain Fatty Acids (SCFAs). In this regard, we evaluated Lupinus albus GOS (LA-GOS) as a natural prebiotic using different animal models. Therefore, the aim of this work was to evaluate the effect of LA-GOS on the gut microbiota, SCFA production, and intestinal health in healthy and induced dysbiosis conditions (an ulcerative colitis (UC) model). Twenty C57BL/6 mice were randomly allocated in four groups (n = 5/group): untreated and treated non-induced animals, and two groups induced with 2% dextran sulfate sodium to UC with and without LA-GOS administration (2.5 g/kg bw). We found that the UC treated group showed a higher goblet cell number, lower disease activity index, and reduced histopathological damage in comparison to the UC untreated group. In addition, the abundance of positive bacteria to butyryl-CoA transferase in gut microbiota was significantly increased by LA-GOS treatment, in healthy conditions. We measured the SCFA production with significant differences in the butyrate concentration between treated and untreated healthy groups. Finally, the pH level in cecum feces was reduced after LA-GOS treatment. Overall, we point out the in vivo health benefits of LA-GOS administration on the preservation of the intestinal ecosystem and the promotion of SCFA production.

scholarly journals Evaluation of the Effects of Different Bacteroides vulgatus Strains against DSS-Induced Colitis

2021 ◽  
Vol 2021 ◽  
pp. 1-15
Author(s):  
Sijia Li ◽  
Chen Wang ◽  
Chengcheng Zhang ◽  
Yanhong Luo ◽  
Qianqian Cheng ◽  
...  
Keyword(s):  
Tissue Injury ◽  
Inflammatory Diseases ◽  
Activity Index ◽  
Genomic Analysis ◽  
Disease Activity Index ◽  
Short Chain Fatty Acids ◽  
Comparative Genomic ◽  
Necrosis Factor Alpha ◽  
Beneficial Effects ◽  
Underlying Causes

Although the strain-dependent effects of Bacteroides vulgatus on alleviating intestinal inflammatory diseases have been demonstrated, the literature has rarely focused on the underlying causes of this effect. In this study, we selected four B. vulgatus strains (FTJS5K1, FTJS7K1, FSDTA11B14, and FSDLZ51K1) with different genomic characteristics and evaluated their protective roles against dextran sulfate sodium- (DSS-) induced colitis. Compared to the other three tested strains, B. vulgatus 7K1 more strongly ameliorated the DSS-induced weight loss, shortening of the colon length, increased disease activity index scores, colonic tissue injury, and immunomodulatory disorder. In contrast, B. vulgatus 51K1 significantly worsened the DSS-induced alterations in the tumor necrosis factor-alpha (TNF-α) concentration and colonic histopathology. A comparative genomic analysis of B. vulgatus 7K1 and 51K1 showed that the beneficial effects of B. vulgatus 7K1 may be associated with some of its specific genes involved in the production of short-chain fatty acids or capsular polysaccharides and enhancement of its survivability in the gut. In conclusion, these findings indicate that the supplementation of B. vulgatus 7K1 is a potentially efficacious intervention for alleviating colitis and provides scientific support for the screening of probiotics with anticolitis effect.

scholarly journals Supplementation of Rhodomyrtus tomentosa fruit polyphenols improved dextran sulfate induced colitis in mice by regulating gut microbiota

2020 ◽  
Vol 189 ◽  
pp. 02023
Author(s):  
Jianing Zhang ◽  
Shuyuan Chai ◽  
Xi Jia ◽  
Yujin Han ◽  
Yufei Liu ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Activity Index ◽  
Intervention Group ◽  
Disease Activity Index ◽  
Experimental Colitis ◽  
Intestinal Wall ◽  
Intestinal Cell ◽  
Control Group ◽  
Immune Balance ◽  
Rhodomyrtus Tomentosa

To investigate the therapeutic effect of polyphenol from the fruits of Rhodomyrtus tomentosa (RTFP) on experimental colitis induced by dextran sulphate sodium(DSS) in mice. A total of 24 Babl/c mice were randomly divided into normal control group, colitis model group and DSS+RTFP intervention group, respectively. The intestinal disease activity index (DAI), pathological histology of colon were investigated, and the changes of gut microbiota in mice were evaluated by 16S rRNA sequencing. Compared with the DSS-induced colitis group, RTFP showed intestinal anti-inflammatory effects, the DAI score was significantly decreased, RTFP improved colitis induced weight loss, fecal imformation and blood in the stool. RTFP relieved the phenomenon of shortening colon length, shortening intestinal wall, and splenomegaly. RTFP intervention inhibited the increase of bacteroides abundance caused by DSS, and remodeled the diversity of gut microbiota. Taken together, RTFP could effectively intervene in experimental colitis induced by DSS in mice, which may be related to the modulating gut microbiota and intestinal cell immune balance.

scholarly journals Dietary Alaska Pollock Protein Attenuates the Experimental Colitis Induced by Dextran Sulfate Sodium via Regulation of Gut Microbiota and Its Metabolites in Mice

Metabolites ◽  
2022 ◽  
Vol 12 (1) ◽  
pp. 44
Author(s):  
Genki Tanaka ◽  
Nozomi Hagihara ◽  
Ryota Hosomi ◽  
Takaki Shimono ◽  
Seiji Kanda ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Dextran Sulfate ◽  
Dextran Sulfate Sodium ◽  
Activity Index ◽  
Body Weight Loss ◽  
Disease Activity Index ◽  
Experimental Colitis ◽  
Short Chain Fatty Acids ◽  
Spleen Weight ◽  
Reduced Body

Protein derived from fish has not only nutritional properties but also health-promoting properties. Few studies have examined the effect of dietary Alaska pollock protein (APP) on the anticolitis effect reported to be associated with metabolic syndrome (MetS). This study investigated the effect of APP intake on colitis symptoms, gut microbiota, and its metabolites in the experimental colitis mouse model induced by dextran sulfate sodium (DSS). Male C57BL/6J mice were divided into three groups: (1) DSS-untreated mice fed an American Institute of Nutrition (AIN) 93G diet (protein source is casein), (2) DSS-treated mice fed an AIN93G diet, and (3) DSS-treated mice fed an APP diet. After the mice were fed the diets for 21 days, experimental colitis was induced by three cycles of 2% DSS administration for 5 days followed by washouts over the course of 5 days. APP-reduced body weight loss increased the disease activity index, and elevated spleen weight and alleviated colon length shortening and colonic tissue damage. Furthermore, APP altered the structure and composition of the microbiota and short-chain fatty acids in feces. Since APP intake alleviates experimental colitis induced by DSS administration through alterations in the gut microbiota and its metabolites, we deduced that APP would inhibit MetS progression via colitis suppression.

scholarly journals Development of Anti-inflammatory Probiotic Limosilactobacillus reuteri EFEL6901 as Kimchi Starter: in vitro and In vivo Evidence

2021 ◽  
Vol 12 ◽  
Author(s):  
Hee Seo ◽  
Hyunbin Seong ◽  
Ga Yun Kim ◽  
Yu Mi Jo ◽  
Seong Won Cheon ◽  
...  
Keyword(s):  
Activity Index ◽  
Body Weight Loss ◽  
Disease Activity Index ◽  
Short Chain Fatty Acids ◽  
Fermented Foods ◽  
Gut Health ◽  
Gut Barrier Function ◽  
Anti Inflammatory

The use of probiotic starters can improve the sensory and health-promoting properties of fermented foods. In this study, we developed an anti-inflammatory probiotic starter, Limosilactobacillus reuteri EFEL6901, for use in kimchi fermentation. The EFEL6901 strain was safe for use in foods and was stable under human gastrointestinal conditions. In in vitro experiments, EFEL6901 cells adhered well to colonic epithelial cells and decreased nitric oxide production in lipopolysaccharide-induced macrophages. In in vivo experiments, oral administration of EFEL6901 to DSS-induced colitis mice models significantly alleviated the observed colitis symptoms, prevented body weight loss, lowered the disease activity index score, and prevented colon length shortening. Analysis of these results indicated that EFEL6901 played a probiotic role by preventing the overproduction of pro-inflammatory cytokines, improving gut barrier function, and up-regulating the concentrations of short-chain fatty acids. In addition, EFEL6901 made a fast growth in a simulated kimchi juice and it synthesized similar amounts of metabolites in nabak-kimchi comparable to a commercial kimchi. This study demonstrates that EFEL6901 can be used as a suitable kimchi starter to promote gut health and product quality.

scholarly journals Nicotinamide Ameliorates Dextran Sulfate Sodium-Induced Chronic Colitis in Mice through Its Anti-Inflammatory Properties and Modulates the Gut Microbiota

2021 ◽  
Vol 2021 ◽  
pp. 1-19
Author(s):  
Kai Kang ◽  
Yue Sun ◽  
Dan Pan ◽  
Bing Chang ◽  
Li-Xuan Sang
Keyword(s):  
Gut Microbiota ◽  
Dextran Sulfate ◽  
Dextran Sulfate Sodium ◽  
Activity Index ◽  
Alpha Diversity ◽  
Short Chain Fatty Acids ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Group ◽  
Chronic Colitis ◽  
Anti Inflammatory

Vitamin B (nicotinamide (NAM)), one of the most important nutritional components for humans, exerts anti-inflammatory activity. This study was aimed at investigating the effect of NAM on the gut microbiota and short-chain fatty acids (SCFAs) in mice with chronic colitis. Colitis was induced in C57BL/6 male mice by administration of 1.5% dextran sulfate sodium (DSS), and the mice were intraperitoneally injected with normal saline (NS) or NAM. NAM treatment ameliorated weight loss and changes in colon length, disease activity index (DAI) score, and histologic scores. Moreover, enzyme-linked immunosorbent assay (ELISA) analysis of LPL cells revealed that the level of interleukin- (IL-) 6, IL-12p70, IL-1β, tumor necrosis factor- (TNF-) α, interferon- (IFN-) γ, IL-21, and IL-17A was increased, while IL-10 was reduced, in the chronic colitis group compared to the control group, but the levels of all these factors were restored after NAM treatment. Then, 16S rRNA sequencing of the large intestinal content was performed, and analysis of alpha diversity and beta diversity showed that the richness of the gut microbiota was decreased in the DSS group compared to the control group and restored after NAM treatment. In addition, NAM modulated specific bacteria, including Odoribacter, Flexispira, and Bifidobacterium, in the NAM+chronic colitis group. Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt) analysis indicated that NAM treatment restored disruptions in the functions of the gut microbiota (replication and repair, cell motility) in mice with DSS-induced colitis. Furthermore, NAM also restored the reduction in valeric acid in mice with DSS-induced chronic colitis. Our results suggest that NAM treatment could alleviate DSS-induced chronic colitis in mice by inhibiting inflammation and regulating the composition and function of gut microbiota.

Protective Effects of Low Dose Vorinostat on Cisplatin-induced Nephrotoxicity in Rats

2020 ◽  
Vol 13 ◽  
Author(s):  
Omnyah M. O. Bashraf ◽  
Ahmed S. Ali ◽  
Hala S. A. Eweis ◽  
Soad S. Ali
Keyword(s):  
Single Dose ◽  
Therapeutic Potential ◽  
Control Group ◽  
Histopathological Analysis ◽  
Protective Effects ◽  
Necrosis Factor Alpha ◽  
In Vivo Models ◽  
Pre Treatment

Background and Aim: Cisplatin (cis-diamminedichloroplatinum [II]; CDDP) is the most widely used drug in cancer chemotherapy. The nephrotoxicity of CDDP is one of its major side effects. Vorinostat (VST) has been reported to have antioxidant and anti-inflammatory effects in both in-vitro and in vivo models. The present study aimed to explore the potential protective effects of VST against CDDP-induced nephrotoxicity in rats. Materials and Methods: The rats were randomly divided into 4 groups; control group, CDDP group (received CDDP 7.5 mg/kg IP single dose 5 days before the end of the experiment), VST group, (received VST 15 mg/kg/day by gastric gavage for 28 days), and CDDP + VST group (received CDDP + VST as above). Blood and kidney samples were collected on the 28th day for biochemical and histopathological examinations. Results : Administration of CDDP single dose (7.5 mg/kg IP) 5 days before the end of the experiment (at day 23) produced a significant decrease in renal glutathione levels and a significant increase in serum urea nitrogen, creatinine, renal malondialdehyde, tumor necrosis factor-alpha, tumor suppressor protein (p53) and nuclear factor kappa B levels compared to the control group. Pre-treatment with VST for 28 days significantly attenuated all unfavorable changes of these parameters. Histopathological analysis showed that VST significantly decreased kidney inflammatory and degenerative changes induced by CDDP. VST also significantly increased Bcl-2 and decreased Caspas-3 immunoexpression in renal tissues. Conclusion: These results suggest that VST alleviates CDDP-induced nephrotoxicity in rats showing a novel therapeutic potential for the management of nephrotoxicity induced by CDDP.

Potential clinical treatment of colitis with cardiotrophin-1

2018 ◽  
Vol 132 (20) ◽  
pp. 2169-2174 ◽  
Author(s):  
Xavier Escoté
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Activity Index ◽  
Disease Activity Index ◽  
Tnf Α ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Factor Α

In a recent issue of Clinical Science, Prieto-Vicente et al. [Clin. Sci. (2018) 132, 985–1001] have smartly demonstrated a potential new use of cardiotrophin-1 (CT-1) to treat and palliate an inflammatory bowel disease such as ulcerative colitis. In that work, authors report that in ulcerative colitic mice, administration of exogenous recombinant CT-1 (rCT-1) promotes lower colon damage and lower disease activity index, reducing systemic levels of tumor necrosis factor α (TNF-α) and also diminishing TNF-α expression in colon together with the reduction in other common inflammation markers. Besides, in vivo rCT-1 administration induces activation of several molecular pathways, including nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) and signal transducer and activator of transcription (STAT)-3, and abolishes bacterial translocation from intestine to other organs, including mesenteric ganglia, lungs, and spleen. Additionally, these results were nicely corroborated in CT-1 depleted mice; in which colon damage and ulcerative colitis severity were greater compared with the wild-type counterparts. All together, these results suggested that CT-1 could be a promising new therapeutic approach for treating inflammatory bowel disease, particularly ulcerative colitis. However, further studies are required to determine its major mechanisms of action and the potential efficacy of CT-1 in human inflammatory bowel diseases.

scholarly journals Gut microbiota changes in inflammatory bowel diseases and ankylosing spondilytis

2021 ◽  
Author(s):  
Anca Cardoneanu ◽  
Catalina Mihai ◽  
Elena Rezus ◽  
Alexandra Burlui ◽  
Iolanda Popa ◽  
...  
Keyword(s):  
Intestinal Microbiota ◽  
Crohn Disease ◽  
Inflammatory Bowel Diseases ◽  
Activity Index ◽  
Disease Activity Index ◽  
Control Group ◽  
Bacterial Group ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Activity Index Score

Background and Aims: Both inflammatory bowel diseases (IBD) and ankylosing spondylitis (AS) can be considered chronic immune disorders sharing common etiopathogenetic mechanisms. Changes in the composition of the intestinal microbiota, which can lead to an abnormal mucosal response, could be the missing link between these two diseases. Our study evaluate the composition of intestinal microbiota and to characterize gut dysbiosis in patients with IBD and AS. Methods: We conducted a prospective case-control study that enrolled 124 patients [20 Crohn’s disease (CD), 27 ulcerative colitis (UC), 28 AS, 17 IBD + AS and 32 controls). Intestinal microbiota analysis was performed by real-time polymerase chain reaction in stool samples. Results: The total quantity of bacteria was decreased in all investigated groups compared to the control group. In studied groups, we noticed an increased percentage of Bacteroides and Escherichia coli (E.coli) and a decreased percentage of Clostridium coccoides, Clostridium leptum, and Faecalibacterium prausnitzii compared to the control group. The percentages of Bifidobacterium (p=0.010) as well as Lactobacillus group (p=0.023) were higher in the L3 form of CD patients. In the E2 form of UC, the quantity of Bacteroides was much higher compared to the E3 form (p=0.004). In AS patients, significant correlations were observed only for the Bifidobacterium species, significantly increased in the axial form compared to peripheral disease (p=0.035). Statistically significant correlations were demonstrated between the Crohn Disease Activity Index score and the total bacterial group (p=0.023, r=-0.507), respectively Bacteroides (p=0.021, r=-0.511) and between the Mayo score and Lactobacillus (p=0.001), respectively E. coli (p=0.001). In IBD + AS group, the Crohn Disease Activity Index score was inversely correlated with the total bacterial group (p=0.010) and directly correlated with Lactobacillus (p=0.047). Conclusions: Intestinal dysbiosis is associated with both IBD and AS. In the association of IBD with AS, dysbiosis is intermediate, but it is associated with the more severe articular disease. Bifidobacterium and Lactobacillus (commonly used as probiotics!) were found to be increased in the association between active IBD and active AS. Further studies are needed to understand how dysbiosis regulates the gut immune system and contributes to intestinal and articular inflammation.

scholarly journals Potential Modulatory Microbiome Therapies for Prevention or Treatment of Inflammatory Bowel Diseases

2021 ◽  
Vol 14 (6) ◽  
pp. 506
Author(s):  
Daan V. Bunt ◽  
Adriaan J. Minnaard ◽  
Sahar El Aidy
Keyword(s):  
Inflammatory Bowel Disease ◽  
Fatty Acids ◽  
Gut Microbiota ◽  
Short Chain Fatty Acids ◽  
In Vivo Models ◽  
Gut Homeostasis ◽  
Bowel Diseases ◽  
Inflammatory Bowel

A disturbed interaction between the gut microbiota and the mucosal immune system plays a pivotal role in the development of inflammatory bowel disease (IBD). Various compounds that are produced by the gut microbiota, from its metabolism of diverse dietary sources, have been found to possess anti-inflammatory and anti-oxidative properties in in vitro and in vivo models relevant to IBD. These gut microbiota-derived metabolites may have similar, or more potent gut homeostasis-promoting effects compared to the widely-studied short-chain fatty acids (SCFAs). Available data suggest that mainly members of the Firmicutes are responsible for producing metabolites with the aforementioned effects, a phylum that is generally underrepresented in the microbiota of IBD patients. Further efforts aiming at characterizing such metabolites and examining their properties may help to develop novel modulatory microbiome therapies to treat or prevent IBD.

Sign in / Sign up

Export Citation Format

Share Document